Drugs giant Novartis pumps up its bet on ‘biosimilars’

Swiss pharmaceutical firms Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious governments.

Drugs giant Novartis pumps up its bet on ‘biosimilars’

Swiss pharmaceutical firms Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious governments.

Novartis’s Sandoz generics unit, among the biggest biosimilars makers, has agreed to license from Poland’s Polpharma Biologics, a version of Biogen’s decade-old Tysabri for multiple sclerosis.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited